



# Novelx Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

Date: 13<sup>th</sup> November, 2025

To,  
The Deputy Manager  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400001.

Sub : Outcome of Board Meeting held on Thursday, 13<sup>th</sup> November, 2025.

Ref: Scrip Code: 536565

Scrip Id: NOVELIX

Respected Sir/Madam,

This is to inform that Board of Directors of the Company in its meeting held on **13<sup>th</sup> November, 2025** at the Registered office of the company i.e., H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029, which commenced at 5:00 P.M. has considered and approved:

1. The Unaudited Financial Results of the company for the quarter and half year ended 30<sup>th</sup> September, 2025 along with the Limited Review Report of the auditors thereon.
2. Considered and approved resignation of Ms. Monam Kapoor (DIN: 09278005), from the position of the Non-Executive Independent Director of the Company with effect from 13<sup>th</sup> November, 2025. A copy of her Resignation Letter is enclosed herewith.
3. Re- constituted the following Committees of the Board of directors of the Company w.e.f. 13<sup>th</sup> November, 2025.
  - i. Reconstitution of the Audit Committee- Post reconstitution, the composition of the Audit Committee shall be as under:

Sr. No.	Name of the Director	Position in Committee	Nature of Directorship
1.	Janardhan Das Kabra	Chairperson	Non-Executive Independent Director
2.	Mayuri Baidya	Member	Non-Executive Independent Director
3.	Jivamohan Divakar Valluri	Member	Non-Executive Non Independent Director

- ii. Reconstitution of the Nomination & Remuneration Committee- Post reconstitution, the composition of the Nomination & Remuneration Committee shall be as under:

Sr. No.	Name of the Director	Position in Committee	Nature of Directorship
1.	Janardhan Das Kabra	Chairperson	Non-Executive Independent Director

## Novelx Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.novelixpharma.com](http://www.novelixpharma.com)





# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314101036)

2.	Mayuri Baidya	Member	Non-Executive Independent Director
3.	Jivamohan Divakar Valluri	Member	Non-Executive Non-Independent Director

- iii. Reconstitution of the Stakeholders Relationship Committee- Post reconstitution, the composition of the Stakeholders Relationship Committee shall be as under:

Sr. No.	Name of the Director	Position in Committee	Nature of Directorship
1.	Jivamohan Divakar Valluri	Chairperson	Non-Executive Non-Independent Director
2.	Janardhan Das Kabra	Member	Non-Executive Independent Director
3.	Mayuri Baidya	Member	Non-Executive Independent Director

The Meeting was concluded at 05:30 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you  
Yours sincerely,

For Novelix Pharmaceuticals Limited



**Venkateshwarlu Pulluru**  
(Whole-time director)  
DIN: 02076871

## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.novelixpharma.com](http://www.novelixpharma.com)



Date:13/11/2025

To,  
The Board of Directors,  
Novelix Pharmaceuticals Limited  
H No: 3-6-237/610, Flat No: 610, 6Th Floor,  
Lingapur LA Builders, Also Known as Amrutha Estates,  
Himayat Nagar, Hyderabad, Telangana- 500029

**Sub.: Resignation letter as an Independent Director of the Company.**

Dear Sir/Madam,

This is to inform the Board that due to my pre-occupation and other personal commitments, I hereby tender my resignation as an Independent Director of the Company with effect from close of the business hours on 13<sup>th</sup> November 2025. Consequently, I also be stepping down as the member of the Audit Committee, Nomination & remuneration Committee and Stakeholders Relationship Committee.

I hereby confirm that there are no other material reasons for my resignation other than those mentioned above.

Please find the list indicating category of my directorship and membership of the Board Committees in the other listed entities before the resignation becoming effective.

Sr. No.	Name of the Listed Entity	Category of the Directorship	Membership of the Board Committee
	PLAZA WIRES LIMITED	Independent Director	1. Audit Committee (Chairperson) 2. Stakeholders Relationship Committee(Chairperson) 3. Nomination and remuneration committee(Chairperson)
	OSCAR GLOBAL LIMITED.	Non Executive Director	1. Audit Committee (Member) 2. Nomination and remuneration committee (Member) 3. Stakeholders Relationship Committee (Member)
	WONDER ELECTRICALS LIMITED	Independent Director	1. Audit Committee (Member) 2. Nomination and remuneration committee (Member) 3. Stakeholders Relationship Committee (Member)
	RAJNISH WELLNESS LIMITED	Independent Director	1. Audit Committee (Member) 2. Nomination and remuneration committee

*Monam*



			(Member)
			3. Stakeholders Relationship Committee (Member)
			4. Risk Management Committee (Member)

Regards

*Monam*

Monam Kapoor  
DIN: 09278005



# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

## Annexure I

**Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.**

Sr. No.	Disclosure Requirement	Details
1.	Name of The Director	Ms. Monam Kapoor
2.	Reason for change viz. Resignation	Ms. Monam Kapoor has resigned from the designation of Independent Non-Executive Director of the Company w.e.f. 13 <sup>th</sup> November 2025 due to pre-occupation and other personal commitments
3.	Effective Date of Resignation	13 <sup>th</sup> November 2025
4.	Brief profile	NA
5.	Disclosure of Relationship between Directors {in case of appointment of Director)	NA
6.	Names of the listed entities in which Ms. Monam Kapoor holds Directorships, indicating the category of Directorship and Membership of Board Committees before the resignation becoming effective:	As Mentioned below:

Names of the listed entities in which Ms. Monam Kapoor holds Directorships, indicating the category of Directorship and Membership of Board Committees before the resignation becoming effective:

Sr. No.	Name of the Listed Entity	Category of the Directorship	Membership of the Board Committee
	PLAZA WIRES LIMITED	Independent Director	1. Audit Committee (Chairperson) 2. Stakeholders Relationship Committee (Chairperson) 3. Nomination and remuneration committee (Chairperson)



## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)  
[www.novelixpharma.com](http://www.novelixpharma.com)





## Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314101036)

	OSCAR GLOBAL LIMITED.	Non Executive Director	1. Audit Committee (Member) 2. Nomination and remuneration committee (Member) 3. Stakeholders Relationship Committee (Member)
	WONDER ELECTRICALS LIMITED	Independent Director	1. Audit Committee (Member) 2. Nomination and remuneration committee (Member) 3. Stakeholders Relationship Committee (Member)
	RAJNISH WELLNESS LIMITED	Independent Director	1. Audit Committee (Member) 2. Nomination and remuneration committee (Member) 3. Stakeholders Relationship Committee (Member) 4. Risk Management Committee (Member)

Serial



## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat  
Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)



**CVS Balachandra Rao & Co.,**  
Chartered Accountants

**Limited Review Report on Standalone Unaudited Quarterly Financial Results of Novelix Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors  
**Novelix Pharmaceuticals Limited**


We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Novelix Pharmaceuticals Limited** for the quarter ended on 30<sup>th</sup> September, 2025, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CVS Balachandra Rao & Co.,  
Chartered Accountants  
ICAI Firm Regd No: 007507S

  
CVS Balachandra Rao  
Partner  
Membership Number: 204580  
UDIN: 25204580BMHZZL7022  
Date: 13/11/2025  
Place: Hyderabad



D.No:3-6-108/1, Flat No:203, Sanatana Eternal, Street No:19, Himayat Nagar, Hyderabad - 500 029. Telangana.

Mobile : 9849035315, 9010624455

Email : cacvsbala@gmail.com, cvsbala67@gmail.com, Website : www.cabrc.in

Branch Office : D.No. 11-33-7B, 2nd Floor, Tatakulavari Street. Samarang Chowk. Vijayawada - 520 001. A.P.





# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314101036)

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2025

Sr. No	Particulars	Rs. (In Lakhs)					
		3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in previous year	6 Months ended	Corresponding 6 Months ended in previous year	Year ended
		30/09/2025 Unaudited	30/06/2025 Unaudited	30/09/2024 Unaudited	30/09/2025 Unaudited	30/09/2024 Unaudited	31/03/2025 Audited
1	<b>Revenue</b>						
	a) Income from Operations (Net)	3,635.89	2,235.12	395.66	5,871.01	455.77	3,071.85
	b) Other Income	3.25	0.00	-8.29	3.25	1.49	1.60
	<b>Total income (a + b)</b>	<b>3,639.14</b>	<b>2,235.12</b>	<b>387.37</b>	<b>5,874.26</b>	<b>457.26</b>	<b>3,073.44</b>
2	<b>Expenses</b>						
	a) Cost of material consumed						-
	b) Excise duty	-	-		-	-	-
	(c) Purchase of stock-in-trade	3,668.48	2,249.50	302.93	5,917.98	339.50	2,922.25
	(d) Changes in inventories of finished goods, work-in- progress and stock-in-trade	-149.67	-71.64	45.33	-221.32	87.30	35.12
	(e) Employee benefits expense	14.18	16.46	1.714	30.63	5.35	6.86
	(f) Finance cost	-	-		-		-
	(g) Depreciation and amortization expense	1.38	1.10	0.48	2.48	0.97	3.80
	(h) Other expenses	32.89	22.76	23.84	55.65	45.65	93.08
	<b>Total Expenses</b>	<b>3,567.25</b>	<b>2,218.17</b>	<b>374.30</b>	<b>5,785.42</b>	<b>478.77</b>	<b>3,061.11</b>
3	<b>Profit and (Loss) before exceptional items and tax</b>	<b>71.89</b>	<b>16.95</b>	<b>13.07</b>	<b>88.84</b>	<b>(21.51)</b>	<b>12.33</b>
4	Exceptional Items						
5	<b>Profit and (Loss) after exceptional items but before Tax</b>	<b>71.88</b>	<b>16.95</b>	<b>13.07</b>	<b>88.84</b>	<b>(21.51)</b>	<b>12.33</b>
6	<b>Tax Expenses</b>						
	(a) Current Tax	18.03	3.54	0.00	21.57	0.00	2.96
	(b) Deferred Tax	0.54	2.70	0.12	3.24	0.92	0.92
7	<b>Total Tax Expenses</b>	<b>18.57</b>	<b>6.23</b>	<b>0.12</b>	<b>24.81</b>	<b>0.92</b>	<b>3.88</b>
8	<b>Net Profit/ (Loss) for the Period (5-7)</b>	<b>53.31</b>	<b>10.71</b>	<b>12.95</b>	<b>64.03</b>	<b>(22.44)</b>	<b>8.45</b>

### Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)







# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

9	<b>Other Comprehensive Income/(Loss)</b>						
	A) (i) Items that will not be reclassified to Profit & Loss						
	(ii) Income tax relating to items that will not be reclassified to profit & loss						
	B) (i) Items that will be reclassified to Profit & Loss						
	(ii) Income tax relating to items that will be reclassified to profit & loss						
10	<b>Total Comprehensive Income/(Loss) (8+9)</b>	<b>52.47</b>	<b>10.71</b>	<b>12.95</b>	<b>64.03</b>	<b>-22.44</b>	<b>8.45</b>
11	<b>Paid up equity share capital (Face Value: Rs. 10 per share)</b>	1,448.00	995.00	995.00	1,448.00	995.00	995.00
12	<b>Earnings per equity share</b>						
	a) Basic	0.37	0.11	0.16	0.44	-0.27	0.08
	b) Diluted	0.49	0.12	0.16	0.59	-0.27	1.09

## NOTES:


1	The above Unaudited Financial Results of the company for the quarter ended September 30th 2025 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on 13 November, 2025.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of

## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)





## Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

	active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website <a href="https://novelixpharma.com">https://novelixpharma.com</a>

By the order of the Board  
For Novelix Pharmaceuticals Limited

*Venkateshwarlu*



**Venkateshwarlu Pulluru**

(Whole-time director)

**DIN: 02076871**

**Date: 13/11/2025**

**Place: Hyderabad**

## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)





# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

## STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2025

Rs. (In Lakhs)

PARTICULARS		As at 30th September 2025	As at 31-March 2025
		(Un Audited)	(Audited)
	<b>ASSETS</b>		
<b>1</b>	<b>Non - current assets</b>		
(a)	Property, plant and equipment	41.88	18.57
(b)	Capital work in progress	-	-
(c)	Investment property	-	-
(d)	Intangible assets	70.95	0.00
(e)	Financial assets	-	-
	(i) Investments	4.32	4.32
	(ii) Loans	-	-
	(iii) Other financial assets	-	-
(f)	Deferred tax Assets (Net)	1.22	4.46
(g)	Other Non-current assets	-	-
	<b>Total non-current assets</b>	<b>118.37</b>	<b>27.35</b>
<b>2</b>	<b>Current assets</b>		
(a)	Inventories	305.64	84.32
(b)	Financial assets		
	(i) Investments	-	-
	(ii) Trade receivables	5,672.91	1,813.69
	(iii) Cash and cash equivalents	145.01	67.86
	(iv) Other balances with banks	-	-
	(v) Loans	878.01	702.31
	(vi) Other financial assets	-	-
(c)	Other Current assests	60.39	25.11
	<b>Total current assets</b>	<b>7061.96</b>	<b>2693.29</b>
	<b>TOTAL ASSETS</b>	<b>7180.33</b>	<b>2720.65</b>
	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
(a)	Share capital	1,448.00	995.00
(b)	Other equity	1,112.96	758.93
	<b>Total Equity</b>	<b>2560.96</b>	<b>1753.93</b>
<b>2</b>	<b>Non-current liabilities</b>		
(a)	Financial liabilities	-	-
	(i) Long-term borrowings	-	-
	(ii) Deferred tax liabilities (net)	-	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	-	-
(c)	Other Non Current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>0.00</b>	<b>0.00</b>
<b>3</b>	<b>Current liabilities</b>		
(a)	Financial liabilities	-	-

## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)





# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314101036)

(i) Borrowings	-	-
(ii) Trade payables	4,549.40	920.11
(iii) Other financial liabilities	-	-
(b) Provisions	69.63	36.60
(c) Other current Liabilities	0.34	10.00
<b>Total current liabilities</b>	<b>4619.37</b>	<b>966.72</b>
<b>Total Liabilities</b>	<b>4619.37</b>	<b>966.72</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>7180.33</b>	<b>2720.65</b>

By the order of the Board  
For Novelix Pharmaceuticals Limited



**Venkateshwarlu Pulluru**

(Whole-time director)

**DIN: 02076871**

**Date: 13/11/2025**

Place: Hyderabad

## Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)





# Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314101036)

## CASH FLOW STATEMENT FOR THE PERIOD ENDED 30th September 2025

Particulars	Rs. (In Lakhs)	
	As at 30-09-2025	As at 31-03-2025
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before Tax and Extraordinary Items	64.03	12.33
Adjustments for:	-	-
Depreciation	2.48	3.80
Interest & Other Income	(3.25)	(1.60)
Loss on Sale of Fixed Assets		
Loss on Sale of Investments & Property		
Profit on sale of mutual funds		
Operating profit before Working Capital Changes	63.25	14.54
Adjustments for:		
Trade and Other receivables	3,629.29	(2,259.35)
Inventories	(221.32)	35.12
Trade & Other payables	(4,070.21)	841.24
Other Current Liabilities	(9.66)	-
Short-Term Provisions	36.27	-
Cash generated from Operations	(635.63)	(1,382.99)
<b>Cash flow before Extraordinary Items</b>	<b>(572.38)</b>	<b>(1,368.46)</b>
Extraordinary Items and Tax		
<b>Net Cash used for Operating activities</b>	<b>(572.38)</b>	<b>(1,368.46)</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Fixed Assets	(96.73)	(10.61)
Sale of Fixed Assets	-	-
Capital Work in progress	-	-
Sale of Investments	-	302.05
Increase / (Decrease) in Security Deposits	-	-
Interest & Other Income	3.25	1.60
<b>Net Cash flow from Investing activities</b>	<b>(93.48)</b>	<b>293.04</b>
<b>C. Cash Flow from Financing Activities:</b>		
Increase in Share Capital	453.00	185.00
Increase in Share Premium	453.00	121.50
Increase / Decrease in Long Term Borrowings	-	-
Share Issue and Preliminary Expenses	-	-

### Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)






## Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

Warrents Issued	(163.00)	825.00
<b>Net Cash flow from Financing activities</b>	<b>743.00</b>	<b>1,131.50</b>
<b>Net Increase in Cash and Cash Equivalents (A+B+C)</b>	<b>77.14</b>	<b>56.08</b>
Cash and Cash Equivalents as at (Opening Balance)	67.86	11.78
Cash and Cash Equivalents as at (Closing Balance)	145.01	67.86

By the order of the Board  
For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru  
(Whole-time director)  
DIN: 02076871  
Date: 13/11/2025  
Place: Hyderabad

### Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.novelixpharma.com](http://www.novelixpharma.com)